Celiac Disease and Autoimmunity: Review and Controversies by Jolanda M. Denham & Ivor D. Hill
AUTOIMMUNITY (TK TARRANT, SECTION EDITOR)
Celiac Disease and Autoimmunity: Review and Controversies
Jolanda M. Denham & Ivor D. Hill
Published online: 17 May 2013
# The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract Celiac disease (CD) is an autoimmune condition
affecting the small intestine, triggered by the ingestion of
gluten, the protein fraction of wheat, barley, and rye. There
is a strong linkage between CD and HLA-DQ2 and HLA-
DQ8 haplotypes. Multiple case reports and small series sug-
gest concordance between CD and other autoimmune disor-
ders. This paper provides a brief overview of the pathogenesis
of CD and reviews the literature regarding associations be-
tween CD and other autoimmune diseases, including the
potential effects of gluten-free diet therapy on the prevention
or amelioration of associated diseases.
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Introduction
Celiac disease (CD) is one of the most common chronic
conditions affecting mankind. It has been identified
throughout the world with the exception of SubSaharan
Africa and East Asia. The prevalence of CD is usually
reported to be about 1 % in the general population, but there
are emerging data to suggest it may actually be increasing in
some developed countries. Clinical manifestations of CD
are highly variable and include both gastrointestinal and
non-gastrointestinal features. There are also people without
any symptoms that have positive CD serology and charac-
teristic histologic changes on small intestinal biopsy. These
have been identified predominantly through screening
groups who are at increased risk for CD. Others have symp-
toms and positive serological tests but do not initially have
the characteristic histological features of mucosal damage. If
these people remain on a regular diet, most will eventually
go on to develop the mucosal changes found in CD over
time. Because of these variations in clinical and laboratory
findings, the precise definition of CD has resulted in much
debate. Most recently, the European Society for Pediatric
Gastroenterology, Hepatology and Nutrition proposed that
CD be defined as follows, “…an immune-mediated system-
ic disorder elicited by gluten and related prolamines in
genetically susceptible individuals and characterized by a
variable combination of gluten-dependent manifestations,
CD-specific antibodies, HLA-DQ2 or HLA-DQ8 haplo-
types, and enteropathy” [1••].
Pathogenesis of CD
As alluded to in the definition, CD is considered an auto-
immune disorder with both a genetic and environmental
component. Evidence for a genetic component is best ex-
emplified by the strong dependence on the presence of the
HLA-DQ2 (encoded by the alleles DQA1*05 and
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DQB1*02) and HLA-DQ8 (DQA1*03 and DQB1-*0302)
haplotypes. More than 95 % of those with CD express HLA-
DQ2 while the remainder expresses HLA-DQ8. However,
about 30–40 % of the general population expresses HLA-
DQ2, so while these HLA genes are necessary, they are not
sufficient for developing CD and clearly non HLA genes are
also involved. To date, at least 39 non-HLA genes have been
identified through genome-wide association studies as
strongly associated with CD [2]. Most of these genes are
involved in control of the innate and adaptive immune
response. However, individually each of these non-HLA
genes is believed to play a relatively small role in CD.
The major environmental trigger is ingestion of “gluten”,
which is the term used to describe the protein fraction of
wheat, barley, and rye. These proteins have high concentra-
tions of glutamine and proline rendering them impossible to
be completely digested by humans. It is these residual
partially digested peptides that initiate innate and adaptive
immune responses in those genetically predisposed to CD.
Other trigger factors may play a role in precipitating disease
and could possibly account for the marked variability in age
of onset and clinical manifestations of disease. Currently,
there is interest in the role of the gut microbiome as an
additional trigger factor contributing to the onset of disease.
Immunopathogenesis of CD
The hallmark of CD is an immune-mediated enteropathy that
involves both the innate and adaptive immune system. Al-
though the precise immune mechanisms that are involved in
the progressive destruction of the small intestinal mucosa
remain to be elucidated, some of the sequences have been
identified. Initially gut paracellular permeability is increased
in CD in part due to peptide-induced CXCR3 activated
upregulation of zonulin, an intestinal peptide involved in
epithelial tight junction control [3]. Paracellular passage of
gliadin peptides follows. One peptide (α-gliadin 31-43) has
been shown to induce apoptosis of enterocytes, upregulate
MHC class I molecules, activate MAP kinase pathway, and
upregulate expression of CD83, a maturation marker of den-
dritic cells [4, 5]. This peptide, and others, enhances IL15
production leading to an expansion of intraepithelial lympho-
cytes (IELs) and triggering the innate immune system. IL15
plays a key role in enhanced cytolytic activity of IELs via
induction of NK receptors on the IEL and also contributes to
promoting the CD4+ T cell adaptive response [6].
The adaptive immune response in CD is characterized
predominantly by a gluten-specific T helper-1 response
leading to production of the pro-inflammatory cytokine
interferon-γ (IFN-γ) [7]. Tissue transglutaminase (TTG),
now known to be the autoantigen in CD, plays a key role
in this process. By means of deamidation, TTG converts
glutamine to glutamic acid at key sites within the gliadin
peptide. This increases the negative charge on the peptide
molecule and enhances binding of the peptide within the
peptide binding groove of the HLA-DQ2 molecule on the
surface of the antigen-presenting cells. This is a prerequisite
for a gluten-specific T cell response as well as a B cell
response that results in production of anti-TTG antibodies
[3]. While these antibodies serve as a highly useful means of
testing for CD, their precise role in the immunopathogenesis
of the condition remains unknown.
While much has been learned about the immune events
that occur in CD, there is still more that is not known. There
is evidence to support the role of IL21 in the pathogenesis of
CD as high levels of this cytokine can be demonstrated in
biopsies from those with active disease that are not on
treatment [8]. However, the mechanism whereby IL21 is
produced and the precise role it plays in the disease process
remains unexplained. Perhaps of more importance is the
need to better understand the interplay between the innate
and adaptive immune system responses and how this leads
to the villous atrophy that is characteristic of CD.
Unraveling the mysteries of CD could offer major insights
into other autoimmune diseases.
CD and Other Autoimmune Diseases
The tendency for multiple autoimmune disorders to occur
over the lifetime of a patient with CD has been well de-
scribed. To date, only hypotheses exist to explain the con-
cordance of separate autoimmune diseases in individuals.
Elucidation of the mechanisms of multiple autoimmune
conditions in the same individual will provide deeper un-
derstanding of the specific conditions themselves.
Celiac Disease and Type 1 Diabetes Mellitus
The association between CD and type 1 diabetes mellitus
(T1DM) is well established [9–13]. A recent review of the
literature reported the prevalence of CD amongst adult and
pediatric T1DM patients between 4.4 and 11 % [14]. A large
Swedish multicenter pediatric study of T1DM patients (n=
300) screened yearly for celiac disease, reported that, over a
5-year period, 6 % of the cohort developed silent CD [13].
Other studies have shown that, in the vast majority (90 %) of
cases, the T1DM diagnosis precedes the celiac diagnosis
[15, 16]. The pathophysiology of the relationship between
T1DM and celiac disease is not fully clear. Genetic studies
show that celiac and T1DM share similar HLA and non-
HLA genetic loci [9], suggesting the existence of autoim-
munity genes. Treatment with a GFD in people with T1DM
and CD is clearly beneficial in those who have symptoms
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associated with CD. Conversely, conflicting evidence exists
as to whether a GFD significantly improves glycemic con-
trol in such cases [12, 16, 17].
Celiac Disease and Addison’s Disease
The majority of Addison’s disease is caused by autoimmune
destruction of the adrenal cortex resulting in adrenal insuf-
ficiency [18, 19]. Studies show an association with HLA-
DQ2 and HLA-DQ8, the same HLA haplotypes necessary
for the presence of CD [18, 20]. Small case series through-
out the world report variable prevalence of CD amongst
patients with Addison’s disease and vice versa [20–24].
Elfstrom, et al. [25] reported the largest study of the occur-
rence of Addison’s disease within a cohort of CD patients.
In their series of adult Swedes, celiac patients were 11.4
times more likely to develop Addison’s disease before or
after their celiac diagnosis compared to non-celiac controls
(95 % confidence interval=4.4–29.6).
Celiac Disease and Thyroid Disorders
The association between CD and thyroid disorders is well
documented. Many studies confirm an increased prevalence
of autoimmune (Hashimoto’s) thyroiditis and Graves dis-
ease within adult [26–31] and pediatric [28, 32]celiac
populations. The converse also appears to be true CD is
found in persons with autoimmune thyroid disorders at
higher rates than the general population [31, 33–35]. As in
the case of T1DM, HLA-DQ2 and DQ8 are disproportion-
ately represented in patients with autoimmune thyroiditis
[36] and Graves disease [37]. In their series of 90 pediatric
patients with thyroid disorders, Larizza et al. reported a
higher prevalence of autoimmune thyroiditis with CD com-
pared to patients with isolated autoimmune thyroiditis in the
general population. They also found CD to be the most
common associated autoimmune disorder. CD occurred mo-
re frequently with autoimmune thyroiditis (6 of 68) com-
pared to Graves disease (1 of 22); however, the comparison
was statistically insignificant [38].
Celiac Disease and Liver Disorders
Cryptogenic hepatitis is the most common liver manifesta-
tion of CD, followed by autoimmune hepatitis (AIH)
[39–41]. Cryptogenic hepatitis has been typified by mild
isolated transaminases with mild lobular and portal inflam-
mation on liver biopsy (celiac hepatitis) [42]. In a large
cohort of 350 pediatric celiac patients, Di Biase et al.
reported isolated transaminase elevations in 40 % of
patients. Adult [41, 43, 44] and pediatric [45, 46] studies
have shown biochemical and histologic reversal of crypto-
genic hepatitis within 1 year of gluten-free diet. An in-
creased prevalence of AIH has been documented in both
pediatric and adult CD cohorts, ranging from 2 to 11.5 %
[39, 45–50]. CD has also been found at higher rates in AIH
compared to non-autoimmune hepatitis populations [45,
51]. It is important to note that the HLA-DQ2 haplotype
found in 95 % of celiac patients shares a strong linkage to
the HLA-DR3 haplotype associated with AIH [52]. Primary
biliary cirrhosis (PBC) and primary sclerosing cholangitis
(PSC) are rarely found in pediatric celiac patients, with rates
between 0.005 and 0.04 % [47, 53]. Prevalence rates for
PBC and PSC are higher in adult studies. Amongst the
South Wales adult population, Kingham et al. [54] reported
a relative prevalence of 3 % for PBC in 143 patients with
CD and, amongst 67 patients, a relative prevalence of 6 %
for PSC. Within a series of 255 adult autoimmune cholesta-
sis patients, 3.5 % had CD (7 primary biliary cirrhosis, 1
primary sclerosing cholangitis and 1 autoimmune
cholangitis) [55]. The pathophysiology of the association
between autoimmune hepatitis and CD remains unclear.
Volta et al. [40] proposed increased intestinal permeability
and circulation of anti-TTG antibodies modify external or
self antigens. These modifications then generate neo-
antigens which, in turn, cause liver damage.
Celiac Disease and Rheumatologic Disorders
Sjogren’s syndrome (SS) is an autoimmune exocrinopathy
typified by dry eyes, dry mouth, and circulating anti-
bodies to intracellular proteins [56]. An association be-
tween Sjogren’s syndrome and CD was reported as
early as 1965 [57]. Since that time, two small series
have reported prevalence rates of CD amongst adult SS
patients as 12 % [58] and 14.4 % [59]. With these
values, Sjogren’s syndrome is considered the most com-
mon rheumatic disorder associated with CD. Fifty-six
percent of SS adult patients also had HLA-DQ2, the
haplotype most commonly found in CD [58]. A number
of case reports describe an association between systemic
lupus erythematosus (SLE) and CD [60–63]. However,
none of the participants in a large series of 103 SLE
patients had CD (biopsy and EMA negative) [64]. The
prevalence of CD amongst patients with chronic arthritis
has been reported as 1.5 % [65] and 2.5 % [66].
Antiphospholipid syndrome (APS) is disorder charac-
terized by clinical (vascular thrombosis, and pregnancy
complications) as well as laboratory (lupus anticoagu-
lant, anticardiolipin) criteria [67]. Shamir et al. [68]
reported a CD prevalence of 14 % amongs 57 adult
with APS. Conversely, 100 % of the EMA positive
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patients had APS. Luft et al. reported CD prevalences in
the following rheumatoid adult populations: 12 % in SS,
6 % in SLE, 7 % in systemic sclerosis (SSc), and 2 %
in rheumatoid arthritis (RA) [58]. Given the frequency
of hypergammaglobulinemia in these disorders, the au-
thors expected a high occurence of false positive anti-
TTG. Interestingly, this was not observed.
Celiac Disease and Dermatologic Disorders
Dermatitis herpetiformis is the dermatologic manifestation
of CD [69•]. The rash typically involves the elbows, exten-
sor surfaces of the forearms, knees, buttocks, back, and
scalp. Lesions begin as groups of 1- to 3-mm papules and
vesicles, but due to intense pruritis, the lesions become the
crusted erosions, excoriations and lichenified tissue that is
typical of the rash visualized by medical personnel. Often,
the pruritis precedes the onset of rash. Lesions can present at
any age, but occur most commonly in young to middle aged
adults [69•, 70, 71]. The rash is chronic, with exacerbations
usually associated with sweating, alternating with long
symptom-free periods. DH in pediatric patients presents
as urticaria, and more commonly purpura involving the
soles, palms, and sides of the fingers. Dermal biopsies of
lesions and surrounding tissues show epidermal tissue
transglutaminase (eTG), the autoantigen for DH, complexed
to immunoglobin A. These complexes trigger an immune
cascade analogous to the tTG-IgA immune cascade in the
gastrointestinal tract [72, 73]. Despite DH spontaneously re-
solving in up to 12 % of patients [74], GFD is the standard
treatment for DH, with resolution in 100 % patients [69•, 71].
Dapsone, 50–100 mg/day, rapidly ameliorates the rash, but
does not halt the intestinal damage caused by ongoing gluten
exposure. Idiosyndratic agranulocytosis can occur rarely with
dapsone usage [71]. Concomittant administration of cimeti-
dine 400 mg TID [75], or vitamin C can prevent dapsone-
induced methemoglobinemia [69•]. Oral steroids do not help
DH, but topical steroid creams can be used as adjuncts to
dapsone [71].
Psoriasis is a T cell-mediated autoimmune disorder
which causes skin erythema, scaling, and occassionally
arthritis [76]. Its association with CD remains unclear.
Some small studies support an association [77–79],
while others show no relationship [80, 81]. A very
large, population-based Swedish study of almost
28,958 adults and children with CD showed a 1.72
hazzard ratio for lifetime psoriasis development amongst
adults and 2.05 amongst children [82]. The psoriasis
could precede or follow the celiac diagnosis. A number
of hypotheses regarding the association of psoriasis and
CD exist: (1) the vitamin D deficiency commonly seen
in CD [83] is known to predispose patients to
development of psoriasis [84, 85], (2) the T cell prolif-
eration and activity in intestinal mucosa may extend
into the blood stream, eventually reaching the dermis
and epidermis, the location of the psoriatic immune
process [86–88], and (3) psoriasis is known to increase
intestinal permeability [89] which is one of the first
steps in the pathogenesis of CD [90].
A few case reports suggest an association between
CD and alopecia acreta (AA) [91, 92]. In a prospective
trial of 256 AA patients, 6 had positive TTG and EMA
with subsequent biopsy confirmation [93]. Seyhan et
al. [94] reported a prevalence of 9 % for vitiligo
amongst adult celiac patients. In a later study of 61
adult and pediatric patients with vitiligo, the same
group reported prevalences rates of 15 % for CD
amongst adult vitiligo patients, and 24 % amongst the
pediatric cohort [95].
Effect of Gluten-Free Diet on Autoimmune Disorders
Numerous papers have investigated the effect of CD
treatment on the incidence and prognosis of various
autoimmune disorders. The data are conflicting. Ventura
et al. prospectively studied 90 adults with biopsy-proven
CD to determine the levels of autoimmune antibodies
associated with type 1 diabetes (glutamic acid decarbox-
ylase, islet cell, anti-insulin) and autoimmune thyroiditis
(anti-thyroperoxidase), at celiac diagnosis, and then at
intervals up to 2 years while on a GFD. They report a
prevalence of type 1 diabetes -related and anti-thyroid
related antibodies of 11.1 and 14.4 %, respectively.
Within 2 years of avoiding gluten, all antibodies nor-
malized. The authors, therefore, surmised that a GFD
was therapeutic against related autoimmunity [96]. In
another large series of 927 adult and pediatric French
celiac patients, Cosnes et al. reported the incidence of
autoimmune diseases to be lower in the compliant
gluten-free diet group compared to the non-compliant
group (5.4/1,000 vs. 11.3/1,000 patient-years during
(P=.002)) [29]. Intriguingly, the authors also showed
that patients first diagnosed with CD when older than
36 years had a decreased cumulative risk of autoim-
mune disorders compared to those diagnosed between
16 and 36 or younger than 16 years old. They proposed
that given the premise that CD is a manifestation of
autoimmune dysregulation, older celiac patients are less
susceptible to autoimmunity, CD, or otherwise. In addi-
tion, with later celiac onset, the integrity of the intesti-
nal barrier has been more competent, reducing the
antigen triggers for various autoimmune disorders [29].
This is in contrast to the findings of Ventura et al. who
studied 909 patients with CD and concluded that
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increased duration of exposure to gluten was related to
a higher prevalence of other autoimmune disorders [47].
Evidence against the protective effect of a GFD exists. In a
prospective study of 27 adult biopsy-proved celiac patients,
Metso et al. found celiac patients had an elevated anti-TPO,
which continued to increase despite nutrition-guided compli-
ance with a GFD. Thyroid atrophy also progressed while on a
GFD. The authors suggest that autoimmune diseases can be
reverted in childhood, but not in adulthood [97]. Valentino et
al. reported improvement of hypothyroidism and reduction of
the thyroxine dosage with a GFD in 5 patients with both CD
and autoimmune thyroiditis [98]. Conversely, in Lirazza et al’s
series of 52 celiac pediatric patients treated with L-thyroxine
for autoimmune thyroiditis, 51 exhibited no difference in their
thyroperoxidase antibody levels or reduction in their L-
thyroxine levels, while 1 patient was able to wean off auto-
immune thyroiditis therapy within 5 years [38]. Other studies
report no difference in autoimmune thyroiditis with a GFD
[30, 32, 97, 99].
In a large cohort of pediatric patients with T1DM, no
difference was observed in hemoglobin A1C (HbA1C) levels,
frequency of ketoacidosis, hypoglycemia, or need for in-
creased insulin dosing between celiac patients and controls
[100]. In a large investigation of arthritis among 356 adult
celiac patients, 49 % reported “some” improvement with a
GFD, and 30 % attributed the improvement to the GFD [101].
Conclusions
CD has been associated with various autoimmune dis-
orders, but there are no good data to establish a cause
and effect relationship between CD, gluten, and these
autoimmune conditions. Current evidence is derived
largely from case reports and small case series, and
there is a paucity of large, population-based prospective
studies necessary to clarify this issue. Review of the
literature shows that CD is most strongly associated
with autoimmune thyroiditis, autoimmune hepatitis, type
1 diabetes, DH, Sjogren’s syndrome, and psoriasis. Giv-
en these specific associations, the propensity toward
multiple autoimmune diseases in any one individual,
and the variable presentations of CD, one should have
a low threshold for screening affected patients with
TTG and/or EMA serology. Current recommendations
are that the diagnosis of CD be confirmed by means
of intestinal histology in all cases prior to starting
treatment with a GFD. Additional large prospective
studies are needed to clarify the relationship between CD
and other autoimmune disorders and the potential effect of
the GFD on these conditions. Further delineation of these
relationships will add to deeper understanding of the individ-
ual diseases and to autoimmunity in general.
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